The Association Between Hemoglobin A1c and Complications Among Individuals With Diabetes and Severe Chronic Kidney Disease
Our data suggest an HbA1c range of 6.7-7.1% (50-54 mmol/mol) to be most favorable for reducing long-term complications in this high-risk population.
Authors
- Nicholas Carlson (ORCID: https://orcid.org/0000-0002-4374-470X)
- Kirsten Nørgaard (ORCID: https://orcid.org/0000-0003-1620-8271)
- Bo Feldt‐Rasmussen (ORCID: https://orcid.org/0000-0002-8267-3027)
- Tobias Bomholt (ORCID: https://orcid.org/0000-0003-0614-4761)
- Mads Hornum (ORCID: https://orcid.org/0000-0002-0123-4007)
- Dea Haagensen Kofod (ORCID: https://orcid.org/0000-0003-0173-8456)
- Jesper Hastrup Svendsen (ORCID: https://orcid.org/0000-0001-8466-8515)
- Thomas Almdal (ORCID: https://orcid.org/0000-0002-7296-4656)
- Christian Torp-Pedersen
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Zealand University Hospital (DK)
- University College Copenhagen (DK)
- IT University of Copenhagen (DK)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-06-07
- DOI
- https://doi.org/10.2337/dc25-0339
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- AstraZeneca
- Dexcom
- Lundbeckfonden
- Novo Nordisk
- Dansk Nefrologisk Selskab
- Augustinus Fonden
- A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
- Vifor Pharma
- H. Lundbeck A/S